Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Molecular and Technological Advances in the Diagnosis and Therapy of...
share announcement

Molecular and Technological Advances in the Diagnosis and Therapy of Cardiovascular Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Molecular Targeted Therapy".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 1945

Special Issue Editor

Dr. Nikolaos Kadoglou

E-Mail Website
Guest Editor
Medical School, University of Cyprus, Nicosia CY2024, Cyprus
Interests: atherosclerotic cardiovascular diseases; biomarkers; atherosclerotic plaque vulnerability; molecular therapies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Atherosclerotic cardiovascular diseases (ASCVDs) are the leading cause of morbidity and mortality in the Western world. The escalating global prevalence of ASCVDs necessitates modern advancements in molecular diagnostics and technology. Primary prevention strategies should prioritize the early identification of atherosclerosis. This is a very demanding process involving genetic, biochemical, pathophysiological and cardiovascular imaging studies, which will enable personalized treatment approaches. Similarly, secondary prevention of ASCVDs should follow with the principles of precision medicine determining the extent of follow-up and the intensity of therapy. Multiple and complex pathophysiologic mechanisms are involved in atherosclerosis progression. Hence, there is still an increasing need to develop and apply more personalized diagnostic tests (molecular and imaging) and therapeutic regimens for ASCVDs. We invite the submission of research and narrative reviews focusing on basic atherosclerosis studies to advance prevention, diagnosis, risk assessment, and treatment through personalized medicine. This Special Issue aims to acquaint medical professionals and researchers with recent advances in ASCVDs within the context of personalized medicine. Original research and reviews are encouraged for this Special Issue. 

Topics include, but are not confined to the following:

  • Experimental atherosclerosis research;
  • Novel biomarkers in ASCVDs;
  • Genomics, GWAS, and population genetics;
  • Atherosclerosis epigenetics and microRNAs;
  • Lipids, lipoproteins, and apolipoproteins;
  • Proteomic and metabolomic exploration of atherosclerosis;
  • Inflammation and/or immunology within atherosclerotic lesions;
  • Arterial expansive and constrictive remodeling;
  • Advances in cardiovascular imaging;
  • Oxidative stress influence;
  • Arterial calcification;
  • Medications stabilizing atherosclerotic plaques. 

Dr. Nikolaos Kadoglou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atherosclerosis
  • personalized medicine
  • molecular diagnostics
  • biomarkers
  • cardiovascular imaging
  • atherosclerotic cardiovascular diseases
  • basic research
  • gene therapy
  • precision medicine for diagnosis and treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1196 KiB  
Article
Associations Between Plasma Levels of NLRP3 Protein, Interleukin-1 Beta and Features of Acute ST-Elevation Myocardial Infarction
by Vyacheslav Ryabov, Yulia Samoilova, Aleksandra Gombozhapova, Anastasiia Nesova and Irina Kologrivova
J. Pers. Med. 2024, 14(11), 1103; https://doi.org/10.3390/jpm14111103 - 13 Nov 2024
Viewed by 402
Abstract
Background. Phenotyping inflammation in ST-elevation myocardial infarction (STEMI) is a challenge for modern cardiology. NLRP3 inflammasome is a proven predictor of adverse outcomes in cardiovascular disease, but its specificity in stratifying inflammatory activity in patients with myocardial infarction (MI) has not been demonstrated. [...] Read more.
Background. Phenotyping inflammation in ST-elevation myocardial infarction (STEMI) is a challenge for modern cardiology. NLRP3 inflammasome is a proven predictor of adverse outcomes in cardiovascular disease, but its specificity in stratifying inflammatory activity in patients with myocardial infarction (MI) has not been demonstrated. The aim of this paper is to describe the levels of NLRP3 protein and IL-1β concentrations and their changes in dynamics and associations with clinical, laboratory and instrumental characteristics of patients with STEMI. Methods. A total of 45 patients with STEMI were enrolled. Concentrations of NLRP3 and IL-1β were evaluated in arterial and venous EDTA blood from the infarct-related coronary and peripheral arteries and veins on days 1, 3 and 7 after MI. Results and Conclusions. The concentrations of markers were higher on the first day after MI with a maximum decrease on the third day. The levels of both markers in venous plasma correlated with those in arterial blood, allowing their routine determination in venous plasma on the first day after MI. IL-1β levels correlated directly with the wall motion index and inversely with left ventricular ejection fraction and stroke volume, which characterize the potential contribution to adverse myocardial remodeling. There were two multidirectional trends in changes in NLRP3 and IL-1β levels during hospitalization. Initially higher levels with a gradual decrease by day 7 were associated with a longer duration of myocardial ischemia and higher plasma troponin I levels. Further evaluation of the long-term outcomes of MI will allow identifying inflammatory factors that input to the development of secondary major adverse cardiac events and will provide a new step in the understanding of inflammatory phenotyping. Full article
(This article belongs to the Special Issue Molecular and Technological Advances in the Diagnosis and Therapy of Cardiovascular Diseases)
►▼ Show Figures

Figure 1

12 pages, 3829 KiB  
Article
The Prognostic Role of Global Longitudinal Strain and NT-proBNP in Heart Failure Patients Receiving Cardiac Resynchronization Therapy
by Nikolaos P. E. Kadoglou, Sjoerd Bouwmeester, Anouk G. W. de Lepper, Marloes C. de Kleijn, Ingeborg H. F. Herold, Arthur R. A. Bouwman, Ioannis Korakianitis, Tim Simmers, Franke A. L. E. Bracke and Patrick Houthuizen
J. Pers. Med. 2024, 14(2), 188; https://doi.org/10.3390/jpm14020188 - 8 Feb 2024
Cited by 3 | Viewed by 1143
Abstract
Background: We aimed to evaluate whether baseline GLS (global longitudinal strain), NT-proBNP, and changes in these after cardiac resynchronization therapy (CRT) can predict long-term clinical outcomes and the echocardiographic-based response to CRT (defined by 15% relative reduction in left ventricular end-systolic volume). Methods: [...] Read more.
Background: We aimed to evaluate whether baseline GLS (global longitudinal strain), NT-proBNP, and changes in these after cardiac resynchronization therapy (CRT) can predict long-term clinical outcomes and the echocardiographic-based response to CRT (defined by 15% relative reduction in left ventricular end-systolic volume). Methods: We enrolled 143 patients with stable ischemic heart failure (HF) undergoing CRT-D implantation. NT-proBNP and echocardiography were obtained before and 6 months after. The patients were followed up (median: 58 months) for HF-related deaths and/or HF hospitalizations (primary endpoint) or HF-related deaths (secondary endpoint). Results: A total of 84 patients achieved the primary and 53 the secondary endpoint, while 104 patients were considered CRT responders and 39 non-responders. At baseline, event-free patients had higher absolute GLS values (p < 0.001) and lower NT-proBNP serum levels (p < 0001) than those achieving the primary endpoint. A similar pattern was observed in favor of CRT responders vs. non-responders. On Cox regression analysis, baseline absolute GLS value (HR = 0.77; 95% CI, 0.51–1.91; p = 0.002) was beneficially associated with lower primary endpoint incidence, while baseline NT-proBNP levels (HR = 1.55; 95% CI, 1.43–2.01; p = 0.002) and diabetes presence (HR = 1.27; 95% CI, 1.12–1.98; p = 0.003) were related to higher primary endpoint incidence. Conclusions: In HF patients undergoing CRT-D, baseline GLS and NT-proBNP concentrations may serve as prognostic factors, while they may predict the echocardiographic-based response to CRT. Full article
(This article belongs to the Special Issue Molecular and Technological Advances in the Diagnosis and Therapy of Cardiovascular Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop